Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Original Research

Accepted on 04 Apr 2025

Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database

in Pharmacology of Anti-Cancer Drugs

Lijun Li
Jiayu Bai
Xuelong Wen
Xuefan Zeng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1585862

Original Research

Accepted on 04 Apr 2025

Multiscale Screening and Identifying Specific Targets for Artesunate in Suppressing Bladder Cancer

in Pharmacology of Anti-Cancer Drugs

Yi Yuan
Guangdi Chu
Qingyue Ma
Zhijuan Liang
Ye Liang
Haitao Niu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1584502

Case Report

Accepted on 04 Apr 2025

Neoadjuvant therapy with ripretinib for gastrointestinal stromal tumor: a case report

in Pharmacology of Anti-Cancer Drugs

Zicheng Zheng
Guanmo Liu
Jie Li
Yixuan He
Chenggang Zhang
Yihua Wang
Weiming Kang
Xin Ye

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1573610

Original Research

Published on 04 Apr 2025

MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study

in Pharmacology of Anti-Cancer Drugs

Rui Bergantim
Sara Peixoto da Silva
Vanessa Pinto
Joana M. Pereira
Diana Sousa
Fernanda Trigo
Rune Matthiesen
José E. Guimarães
M. Helena Vasconcelos

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1465814

224 views

Original Research

Published on 04 Apr 2025

Development and validation of hierarchical signature for precision individualized therapy based on the landscape associated with necroptosis in clear cell renal cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Gao-Sheng Yao
Jun-Shang Dai
Liang-Min Fu
Juan Lin
Zhi-Ping Tan
Lei Dai
Wei Chen
Jun-Hang Luo
Jin-Huan Wei

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1470145

Original Research

Accepted on 03 Apr 2025

LINC01559 Drives Osimertinib Resistance in NSCLC Through a ceRNA Network Regulating miR-320a/IGF2BP3 Axis

in Pharmacology of Anti-Cancer Drugs

Leidi Xu
Yibo Zhang
Liangliang Xing
Ying Zhou
Ning Chang
Hangtian Xi
Xiangrui Xu
Jian Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1592846

Original Research

Published on 03 Apr 2025

Norcantharidin inhibits TOP2A expression via H3K27me3 mediated epigenetic regulation to alleviate the progression of hepatocellular carcinoma

in Pharmacology of Anti-Cancer Drugs

Ruibing Wu
Hengye Yuan
Yuehua Wang
Xianggang Gou
Wanhua Hou
Zhongzheng Zhou
Xinran Wang
Xiuling Deng
Changshan Wang
Haisheng Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1541298

282 views

Original Research

Published on 03 Apr 2025

Synergistic anticancer potential of biogenic nanoparticles and cryptomeridiol from Sphaeranthus indicus: targeting gastric cancer through apoptosis and cell cycle arrest

in Pharmacology of Anti-Cancer Drugs

Pan Zhao
Jigang Wang
Chang Zou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1565308

171 views

Original Research

Published on 03 Apr 2025

From COPD to cancer: indacaterol’s unexpected role in combating NSCLC

in Pharmacology of Anti-Cancer Drugs

Chenghao Liu
Jiaqi Huang
Pengjie Cai
Min Jiang
Honglei Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1579126

156 views

Original Research

Published on 02 Apr 2025

Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation

in Pharmacology of Anti-Cancer Drugs

Ni Zhang
Xinchen Tian
Fen Liu
Xiaohan Jin
Jiaqi Zhang
Lingli Hao
Shulong Jiang
Qingbin Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1514997

153 views

Original Research

Published on 02 Apr 2025

Research mapping of cannabinoids and endocannabinoid system in cancer over the past three decades: insights from bibliometric analysis

in Pharmacology of Anti-Cancer Drugs

Yaqian Tan
Hui Xia
Qi Song

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1540619

172 views

Original Research

Published on 02 Apr 2025

Discovery of benzethonium chloride as a potent STAT3 inhibitor for the treatment of HNSCC

in Pharmacology of Anti-Cancer Drugs

Yuefeng Han
Shumin Li
Deshang Chen
Mingjie Zhang
Guoying Han
QianQian Xu
Xianming Ge
Mengli Wang
Yan Pan
Sien Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1569570

215 views

Original Research

Published on 02 Apr 2025

Therapeutic potential and mechanistic insights of silibinin targeting cancer-associated fibroblasts in colorectal cancer

in Pharmacology of Anti-Cancer Drugs

Shenglan He
Jianmei Ji
Kaisi Zhu
Youlan Chen
Xiaowen Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1527871

183 views

Original Research

Accepted on 01 Apr 2025

Elucidation of the Mechanism Underlying the Promotion of ferroptosis and Enhanced Antitumor Immunity by Citrus Polymethoxyflavones in CRC Cells

in Pharmacology of Anti-Cancer Drugs

SENLING FENG
Yingying Duan
Yu Wu
Jiaqi Tian
Yuqin Yin
Zhongwen Yuan
Wenting Zhu
Suyue Zhou
Chen Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1571178

Original Research

Published on 01 Apr 2025

New prognostic features and personalized treatment strategies of mitochondrial related genes in colorectal cancer patients

in Pharmacology of Anti-Cancer Drugs

Qizheng Xu
Zhiwen Wang
Shan-Tao Huang
Jia-Yu Shi
Yan Zhu
Han-Qing Pang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1540767

170 views

Systematic Review

Published on 01 Apr 2025

Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas/leukemia: a meta-analysis

in Pharmacology of Anti-Cancer Drugs

Jingfei Wang
Hai-en Cheng
Yanhua Sun
Zhenfeng Li
Yunke Zang
Yuying Zhao
Guimao Yang
Zhijun Liu
Yaqi Sun
Yanli Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1559056

285 views